Compare RNXT & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNXT | GSIW |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4M | 42.6M |
| IPO Year | 2021 | 2022 |
| Metric | RNXT | GSIW |
|---|---|---|
| Price | $1.42 | $18.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.25 | N/A |
| AVG Volume (30 Days) | ★ 317.3K | 6.9K |
| Earning Date | 05-14-2026 | 08-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,123,000.00 | N/A |
| Revenue This Year | $194.66 | N/A |
| Revenue Next Year | $279.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2511.63 | N/A |
| 52 Week Low | $0.70 | $0.05 |
| 52 Week High | $1.45 | $38.55 |
| Indicator | RNXT | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 79.87 | 38.57 |
| Support Level | $0.82 | $15.24 |
| Resistance Level | N/A | $33.00 |
| Average True Range (ATR) | 0.09 | 1.52 |
| MACD | 0.04 | -0.18 |
| Stochastic Oscillator | 98.25 | 31.89 |
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.